Article
Pharmacology & Pharmacy
Seong Soo A. An, Kyu Hwan Shim, Shinwoo Kang, Young Kyo Kim, Lalita Subedi, Hyewon Cho, Seong-Min Hong, Mario A. Tan, Raok Jeon, Keun-A Chang, Sun Yeou Kim
Summary: This study demonstrated that SPA1413 has potent inhibitory effects on amyloid-beta fibrilization and oligomerization, as well as neuroprotective effects in cell and animal models of Alzheimer's disease. The results strongly suggest the potential of repurposing SPA1413 for the treatment of Alzheimer's disease due to its anti-amyloidogenic and anti-neuroinflammatory actions, supported by its fast-track status from the US FDA for cancer treatment.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Ruolan Li, Feng Lu, Xue Sun, Liying He, HuXinyue Duan, Wei Peng, ChunJie Wu
Summary: The study successfully developed hydroxy-alpha-sanshool liposomes (HAS-LPs) that can improve learning and memory disorders in an Alzheimer's disease (AD) model, suggesting potential clinical applications for these nanoparticles.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Giovanni Schepici, Valentina Contestabile, Andrea Valeri, Emanuela Mazzon
Summary: Ginger compounds have shown beneficial effects in treating and preventing Alzheimer's Disease and Vascular Dementia, potentially reducing the risk of dementia.
Review
Biochemistry & Molecular Biology
Jana Klose, Carola Griehl, Steffen Rossner, Stephan Schilling
Summary: Neurodegenerative disorders, such as Parkinson's disease, Huntington's disease, and Alzheimer's disease, are urgent medical needs worldwide. Despite advancements in understanding the development and pathology of these diseases, there are currently no treatments available to stop the progression of Alzheimer's disease. The recent approval of sodium oligomannate for Alzheimer's disease treatment in China highlights the potential value of natural products in the treatment of neurodegenerative disorders. Many clinical studies are currently exploring the use of natural compounds, particularly those with anti-inflammatory and anti-oxidative activities, for neuroprotection.
News Item
Multidisciplinary Sciences
Sara Reardon
Summary: The study indicates that the amyloid-targeting drug candidate has the potential to slow down cognitive decline in certain individuals, but concerns remain regarding its possible side effects.
Article
Engineering, Biomedical
Fuxin Jiang, Jian Ren, Yachai Gao, Jinna Wang, Yiping Zhao, Fengying Dai
Summary: The study successfully constructs stimuli-responsive self-assembled nanovesicles for delivering water-soluble drugs to prevent efflux transport of brain barriers in Alzheimer's disease brain microenvironment. The smart multi-drug delivery vesicle shows promising potential for AD treatment and other central nervous system disorders.
BIOACTIVE MATERIALS
(2021)
Article
Neurosciences
Hafsa Amat-ur-Rasool, Mehboob Ahmed, Shahida Hasnain, Wayne G. Carter
Summary: Different ChEIs have varying potency in inhibiting AChE, with synergistic effects observed in dual-drug combinations. Dual-drug combinations may offer a novel and more cost-effective approach to treating AD patients.
Article
Clinical Neurology
Jiansong Fang, Pengyue Zhang, Quan Wang, Chien-Wei Chiang, Yadi Zhou, Yuan Hou, Jielin Xu, Rui Chen, Bin Zhang, Stephen J. Lewis, James B. Leverenz, Andrew A. Pieper, Bingshan Li, Lang Li, Jeffrey Cummings, Feixiong Cheng
Summary: This study develops a network-based artificial intelligence framework that integrates multi-omics data with protein-protein interactome networks to accurately infer drug targets affected by GWAS-identified variants, leading to the discovery of new therapeutics. Through applying this approach to AD, 103 validated ARGs are identified, and three drugs are found to be significantly associated with decreased risk of AD.
ALZHEIMERS RESEARCH & THERAPY
(2022)
News Item
Multidisciplinary Sciences
Asher Mullard
Summary: Pharmaceutical companies are submitting their anti-amyloid drug candidates for approval, but concerns remain over the controversial precedent set by Biogen's aducanumab.
Review
Biochemistry & Molecular Biology
Wenjing Su, Wenhao Xu, Enshuo Liu, Weike Su, Nikolay E. Polyakov
Summary: Natural bioactive compounds such as carotenoids have been used for the treatment of Alzheimer's disease. However, their low solubility, poor stability, and low bioavailability hinder their effectiveness. Nano-drug delivery systems have been developed to enhance the solubility, stability, permeability, and bioavailability of carotenoids for the treatment of Alzheimer's disease. This review summarizes the recent developments in carotenoid nano-drug delivery systems, including polymer, lipid, inorganic, and hybrid systems, and their therapeutic effects on Alzheimer's disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Fisheries
Dhivya Bakthavachalam, Sivakumar Arumugam
Summary: Peptide-based drugs have shown great potential in pharmaceutical industry for treating neurodegenerative disorders, type 2 diabetes, and blood pressure. This study focused on isolating and characterizing marine peptides from Scylla serrata crab species. Various techniques such as thin-layer chromatography, infrared spectroscopy, NMR analysis, UPLC, and Sephadex G-25 purification were employed. The samples displayed significant antioxidant activity, and the molecular weight of the peptides was determined to be between 75 and 100 kDa. Prospective compounds need further screening for potential drug candidates for Alzheimer's disease.
AQUACULTURE INTERNATIONAL
(2023)
Review
Geriatrics & Gerontology
Yuehua Huang, Xiaoyu Li, Guifei Luo, Junli Wang, Ranhui Li, Chuyi Zhou, Teng Wan, Fenglian Yang
Summary: This paper reviews the recent research progress on pyroptosis and focuses on the pathogenic roles of pyroptosis in Alzheimer's disease (AD) and the potential of targeted inhibition of inflammasome-dependent pyroptosis for AD treatment.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Article
Chemistry, Multidisciplinary
Mario Fernandes, Ivo Lopes, Luana Magalhaes, Marisa P. Sarria, Raul Machado, Joao Carlos Sousa, Claudia Botelho, Jose Teixeira, Andreia C. Gomes
Summary: Exosomes-like liposomes were developed for controlled delivery, efficiently encapsulating curcumin and showing potential neuroprotection without toxicity. These innovative carriers are stable, protect the cargo, and are uptaken by neuronal cells, offering a positive alternative strategy for Alzheimer's disease therapy.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Clinical Neurology
Johanna Thunell, Yi Chen, Geoffrey Joyce, Douglas Barthold, Paul G. Shekelle, Roberta Diaz Brinton, Julie Zissimopoulos
Summary: The study identified 29 drug classes associated with increasing or decreasing ADRD risk, with a need for further research in certain areas. Some areas of study still have limited evidence and require more data to support conclusions.
ALZHEIMERS & DEMENTIA
(2021)
Review
Chemistry, Medicinal
Barbara Miziak, Barbara Blaszczyk, Stanislaw J. Czuczwar
Summary: Alzheimer's disease is a progressive neurodegenerative disorder associated with cognitive and functional impairment and neuropsychiatric symptoms. Current pharmacological treatments are symptomatic, focusing on N-methyl-D-aspartate receptor antagonist and cholinesterase inhibitors. Research is exploring approved drugs for other conditions, as well as investigating novel compounds. Approved drugs like bexarotene and antidepressants, along with dietary supplements, have shown potential in reducing symptoms and enhancing cognition. An investigational compound, CN-105, has shown promising results in preclinical studies for Alzheimer's disease.